Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity

NCT07919405 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07919405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 11, 2026
Completion date
July 13, 2028
Enrollment
1,408 (estimated)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 4 arms.

  • CagriSema ExperimentalCagriSema

    Participants will receive CagriSema subcutaneously once weekly.

  • Semaglutide Active comparatorSemaglutide

    Participants will receive semaglutide subcutaneously once weekly.

  • Cagrilintide Active comparatorCagrilintide

    Participants will receive cagrilintide subcutaneously once weekly.

  • Placebo Placebo comparatorPlacebo

    Participants will receive placebo subcutaneously once weekly.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP) From baseline (week 0) to week 32

    Measured in millimeters of mercury (mmHg).

Lead sponsor's other trials

Novo Nordisk A/S, most recent start first.

Similar trials

Same condition (Hypertension) and phase, most recent start first.